Biofidelity Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biofidelity Ltd. - overview
Established
2019
Location
Cambridge, Cambridgeshire, UK
Primary Industry
Biotechnology
About
Based in Cambridge, UK, and founded in 2019 by co-founders Barnaby Balmforth (CEO) and Cameron Frayling, Biofidelity Ltd. operates as a provider of diagnostic assays for disease detection and monitoring to assess and implement therapies that enable the multiplexed detection of genetic mutations without performing DNA sequencing. In February 2024, Biofidelity Ltd. raised GBP 19.
20 million in venture funding from Agilent Technologies, Octopus Ventures, BlueYard Capital, and Longwall Ventures. The company provides a wide range of genomic testing services, such as ASPYRE technology for actionable biomarker detection, ASPYRE-Lung for lung cancer biomarker analysis, and ENSPYRE for genomic precision testing.
Current Investors
Longwall Ventures , Innovate UK, Agilent Technologies
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Molecular Science, Genetics & Gene Therapy, Diagnostic Equipment
Website
www.biofidelity.com/
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.